Iovance biotherapeutics, inc. (IOVA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Costs and expenses
Operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,449

1,616

1,956

-

2,459

779

434

1,472

1,377

1,376

2,250

2,269

5,814

10,561

658

-

-

Research and development expenses

56,952

54,238

41,582

39,298

30,905

27,418

27,947

24,551

19,912

20,696

16,679

18,647

15,593

9,805

8,481

4,463

4,192

4,057

4,960

4,055

2,398

2,698

354

493

302

1,384

250

250

270

250

250

270

886

1,755

0

0

0

-

-

General and administrative expenses

13,858

10,872

10,029

10,867

9,081

7,525

7,113

6,827

6,965

5,375

5,664

4,934

5,289

6,118

10,498

7,264

2,818

4,422

2,683

2,385

2,900

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of Lion transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,700

-

0

-

0

-

-

-

-

-

-

-

-

Impairment of intangible asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

160

0

0

0

-

-

Total costs and expenses

70,810

65,110

51,611

50,165

39,986

34,943

35,060

31,378

26,877

26,071

22,343

23,581

20,882

15,923

18,979

11,727

7,010

8,479

7,643

6,440

5,298

4,868

2,803

2,110

2,259

11,497

9,409

1,029

704

1,722

1,627

1,646

3,136

4,184

5,814

10,561

658

167

84

Loss from operations

-70,810

-65,110

-51,611

-50,165

-39,986

-34,943

-35,060

-31,378

-26,877

-26,071

-22,343

-23,581

-20,882

-15,923

-18,979

-11,727

-7,010

-8,479

-7,643

-6,440

-5,298

-

-2,803

-2,110

-

-11,497

-9,409

-1,029

-704

-1,722

-1,627

-1,646

-3,136

-4,184

-5,814

-10,561

-658

-167

-84

Other income
Interest income, net

1,215

1,542

2,124

2,614

3,036

2,368

1,230

718

362

217

194

204

198

234

221

164

126

119

8

73

0

-

5

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest (expense) income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

104

341

-

126

110

88

119

31

0

0

0

-

Change in fair value of derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

7,659

1,595

1,927

-2,548

-1,645

3,546

-398

93

16

0

Amortization of discount on convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

497

0

2,401

2,598

0

0

0

-

Cost to induce exchange transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,295

0

-

0

0

-

-

-

-

-

-

-

Financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

515

0

-

-

-

-

-

-

-

Private placement costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

920

0

0

-563

0

Total other income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-2,399

-341

5,188

953

1,319

-2,636

-4,166

-4

-398

93

-546

-

Net Loss

-69,600

-63,612

-49,487

-47,551

-36,950

-32,575

-33,830

-30,660

-26,515

-25,854

-22,149

-23,377

-20,684

-15,689

-18,758

-11,563

-6,884

-8,360

-7,635

-6,367

-5,298

-4,867

-2,798

-2,110

-2,259

-11,497

-9,409

-3,429

-1,046

3,466

-673

-327

-5,772

-8,351

-5,818

-10,959

-564

-713

-84

Deemed dividend related to beneficial conversion feature of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

49,454

-

-

-

0

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Net Loss Attributable to Common Stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-68,212

-

-

-

-7,635

-

-

-

-

-

-

-

-

-

-1,046

-

-

-

-

-

-

-

-

-

-

Net Loss Per Common Share, Basic and Diluted

-0.55

-0.51

-0.40

-0.38

-0.30

-0.26

-0.36

-0.34

-0.31

-0.36

-0.35

-0.37

-0.33

-0.33

-1.15

-0.23

-0.14

-0.18

-0.16

-0.14

-0.14

-0.17

-0.11

-0.09

-0.11

2.66

-0.66

-4.19

-1.28

-10.67

-0.86

0.00

7.39

-0.11

-0.07

-0.15

-0.01

-0.01

0.00

Weighted Average Common Shares Outstanding, Basic and Diluted

126

126

124

123

123

119

95

90

84

72

63

62

62

62

59

51

48

-129,855

47,272

45,082

37,678

-71,468

26,632

24,137

20,798

23,260

14,152

818

818

846

782

782

781

79,380

78,299

74,074

71,941

72,002

71,860